You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
基蛋生物(603387.SH):上半年自研自產的Metis6000全自動生免流水線,截止8月30日已累計裝機30條
格隆匯 09-12 19:40

格隆匯9月12日丨基蛋生物(603387.SH)在半年度業績網上説明會上表示,今年上半年,公司正式發佈自研自產的Metis6000全自動生免流水線,截止2023年8月30日已累計裝機30條,其中二級及以上醫院覆蓋率為55%左右。Metis6000競爭優勢主要體現在以下兩方面:一方面,Metis6000集成MAGICL6200免疫模塊及CM-1000生化模塊,搭載全新的SH80樣本處理系統和SHC200離心開蓋模塊,具備去蓋、離心、實時急診檢測、視覺識別等功能,助力醫療質量與運營效率提升;相比於傳統流水線,Metis6000具有高效、智能、輕便、靈活的特點,雙模塊佔地面積僅需3.3㎡,增加一個生化/免疫模塊僅1.1㎡,同時配備豐富的生化免疫檢測試劑套餐,一管血可檢測近200項生化和免疫項目,可廣泛應用於三級醫院急診檢驗、二級及以下醫院中心實驗室、民營、體檢中心等。另一方面,Metis6000的生化、發光、軌道等模塊均為公司自研自產,憑藉優異的產品性能,差異化的市場定位和更高的性價比,積極抓住基層醫院、二級及以上醫院檢驗科對高性價比流水線的需求,讓流水線惠及更多醫學實驗室。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account